Kodak to partner in PACS with Perot Systems
Kodak to partner in PACS with Perot SystemsFilm and PACS company Eastman Kodak has signed a letter of intent with Perot Systems to work together on installing institution-wide PACS networks. Dallas-based Perot Systems will provide networking and
Kodak to partner in PACS with Perot Systems
Film and PACS company Eastman Kodak has signed a letter of intent with Perot Systems to work together on installing institution-wide PACS networks. Dallas-based Perot Systems will provide networking and integration services in large-scale PACS situations. The deal allows Kodak to offer customers both PACS and systems integration services, according to the Rochester, NY-based firm.
In other Kodak news, the firm is partnering with archiving firm Storage Technology of Louisville, CO, to bring support for digital linear tape to Kodak's long-term archiving offerings. The DLT addition will complement Kodak's other DICOM-compliant, long-term storage products, which include CD libraries.
The DLT subsystem employs the StorageTek automated cartridge system to meet department, hospital, or enterprise-wide long-term archiving needs, according to Kodak. Like the other two archiving levels in the Kodak Digital Science medical image and information library, the long-term archiving offering features JPEG data compression, autorouting, prefetching, and support for information transfer via Ethernet, 100 BaseT, ATM, T1, and ISDN lines.
- Search again
- Homepage
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
